secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-08-11T20:06:07+00:00
Accession:  0001398733-26-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q2 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026
--------------------------------------------------------------------------------

- Q2 revenue $13.8M vs $10.0M; manufacture/supply $11.9M, license/royalty $1.3M.
- Net loss $22.9M ($0.18/sh) includes $11.7M one-time debt extinguishment; ex-item net loss $11.2M.
- Non-GAAP adjusted EBITDA loss improved to $5.2M from $9.3M; cash $98.5M at June 30.
- Anaphylm PK study met primary endpoints; human factors study improved; NDA resubmission on track for Q3 2026.
- FY2026 guidance unchanged: revenue $46-50M, adj. EBITDA loss $35-30M; manufacturing 48M doses vs 37M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/0001398733-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/aqst-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer